IP Library Granted Patent US 12,262,978
Granted Patent B2
US 12,262,978 · App. 18/400,507 · Granted Apr 1, 2025

Absolute blood volume estimation device and method

Inventors: Yossi Chait (Longmeadow, MA); Joseph Horowitz (Amherst, MA); Christopher V. Hollot (East Hampton, MA); Hamed Samandari (Mason, OH); Michael J. Germain (Hampden, MA); Daniel Schneditz (Graz, AT)
Assignees: University of Massachusetts; Analiza, Inc.; Medical University of Graz
A61B5/02028A61B5/0275A61B5/14535A61B5/6866A61M1/1613A61M1/267A61M1/361A61M2205/3389A61M2205/50A61M2205/52A61M2230/20A61M2230/207
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,262,978
App. No.
18/400,507
Granted
Apr 1, 2025
Kind
B2
Abstract

Absolute blood volume in dialysis patients is a useful patient attribute to know for dialysis treatment, diagnosis, adjustments, etc. In some cases, it is difficult or impossible to directly determine absolute blood volume. Estimating absolute blood volume may be used to overcome the inability to directly determine the absolute blood volume. Estimating absolute blood volume may include obtaining a series of measurements of hemoconcentration of a patient over a time period, and estimating parameters for a physiological model based on the series of measurements. The absolute blood volume of the patient may be determined using the physiological model.

Claims (16)

1. A method for estimating absolute blood volume at a dialysis machine, the method comprising:

injecting, using a pump, a predetermined volume of indicator liquid into a blood stream of a patient;

obtaining, via a sensor, a series of measurements of hemoconcentration of at least one blood characteristic of the patient over a time period, the series of measurements including a hemoconcentration at a dilution test time during the time period, and the series of measurements of hemoconcentration based on blood volume compared to the predetermined volume of indicator liquid;

estimating parameters for a physiological model based on the series of measurements, the parameters including the hemoconcentration at the dilution test time, a volume of a first compartment and a volume of a second compartment at the dilution test time and at an dilution injection time of the time period;

determining an absolute blood volume of the patient at the dilution test time using the physiological model and the series of measurements of hemoconcentration; and

outputting the absolute blood volume on a display portion of the dialysis machine.

2. The method of claim 1 , further comprising, prescribing, at the dialysis machine, a dialysis treatment action for the patient based on the absolute blood volume at the dilution test time.

3. The method of claim 1 , further comprising, modifying, at the dialysis machine, a dialysis treatment action for the patient automatically based on the absolute blood volume.

4. The method of claim 1 , wherein the dilution test time is ten minutes after the dilution injection time, and wherein the injection occurs at the dilution injection time.

5. The method of claim 1 , wherein the time period includes a period before the dilution injection time and the series of measurements include measurements taken during the period before the dilution injection time for a baseline.

6. The method of claim 1 , wherein the estimated parameters are unique to the patient at the dilution injection time.

7. The method of claim 1 , wherein the estimated parameters include a blood exchange between the first and second compartments, a fluid exchange with interstitial space, and a time delay.

8. The method of claim 1 , wherein estimating the parameters includes fitting the physiological model to the series of measurements.

9. The method of claim 8 , wherein fitting the physiological model to the series of measurements includes performing a nonlinear least squares fit and minimizing a root-mean-square error between the series of measurements and blood volume estimates resulting from the physiological model.

10. The method of claim 1 , wherein estimating the parameters include using a patient-specific attribute including gender, age, weight, ethnicity, or comorbidity.

11. The method of claim 1 , wherein the at least one blood characteristic includes at least one of a relative blood volume, a blood volume monitor (BVM) measurement, a hematocrit measurement, or a hemoconcentration measurement.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2025
From: GERMAIN, MICHAEL J.
To: ANALIZA, INC.
Reel/Frame 070307/0546 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2025
From: SCHNEDITZ, DANIEL
To: MEDICAL UNIVERSITY OF GRAZ
Reel/Frame 070307/0687 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2025
From: CHAIT, YOSSI; HOROWITZ, JOSEPH; HOLLOT, CHRISTOPHER V.; SAMANDARI, HAMED
To: UNIVERSITY OF MASSACHUSETTS
Reel/Frame 070307/0872 →
CONFIRMATORY LICENSE Recorded Jan 29, 2024
From: UNIVERSITY OF MASSACHUSETTS AMHERST
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 066377/0392 →
Continuity (3)
Division 16617904
Provisional Application 62514322 · Jun 2, 2017
Related Publication 20240131239A1 · Apr 25, 2024
References Cited (32)
US 5326476A · Grogan et al. · 1994 [cited by applicant]
US 6246894B1 · Steuer et al. · 2001 [cited by applicant]
US 20020085951A1 · Gelfand et al. · 2002 [cited by applicant]
US 20090101577A1 · Fulkerson et al. · 2009 [cited by applicant]
US 20200054814A1 · Abohtyra et al. · 2020 [cited by applicant]
US 20200086027A1 · Chait et al. · 2020 [cited by applicant]
WO WO0247609A2 · 2002 [cited by applicant]
WO WO2014204841A1 · 2014 [cited by applicant]
WO WO2015179401A1 · 2015 [cited by applicant]
WO WO2015179523A1 · 2015 [cited by applicant]
WO WO2018223046A1 · 2018 [cited by applicant]
“U.S. Appl. No. 16/545,184, Examiner Interview Summary mailed Apr. 26, 2022”, 2 pgs. [cited by applicant]
“U.S. Appl. No. 16/545,184, Final Office Action mailed Apr. 6, 2022”, 13 pgs. [cited by applicant]
“U.S. Appl. No. 16/545,184, Non Final Office Action mailed Oct. 18, 2022”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 16/545,184, Non Final Office Action mailed Nov. 23, 2021”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 16/545,184, Response filed Mar. 23, 2022 to Non Final Office Action mailed Nov. 23, 2021”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 16/545,184, Response filed Oct. 5, 2022 to Final Office Action mailed Apr. 6, 2022”, 14 pgs. [cited by applicant]
“U.S. Appl. No. 16/617,904, Ex Parte Quayle Action mailed Jul. 24, 2023”, 4 pgs. [cited by applicant]
“U.S. Appl. No. 16/617,904, Non Final Office Action mailed Oct. 13, 2022”, 15 pgs. [cited by applicant]
“U.S. Appl. No. 16/617,904, Notice of Allowance mailed Sep. 27, 2023”, 6 pgs. [cited by applicant]
“U.S. Appl. No. 16/617,904, Preliminary Amendment filed Nov. 27, 2019”, 5 pgs. [cited by applicant]
“U.S. Appl. No. 16/617,904, Response filed Apr. 12, 2023 to Non Final Office Action mailed Oct. 13, 2022”, 10 pgs. [cited by applicant]
“U.S. Appl. No. 16/617,904, Response filed Sep. 12, 2023 to Ex Parte Quayle Action mailed Jul. 24, 2023”, 4 pgs. [cited by applicant]
“U.S. Appl. No. 16/617,904, Response filed Sep. 16, 2022 to Restriction Requirement mailed Jul. 18, 2022”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/617,904, Restriction Requirement mailed Jul. 18, 2022”, 9 pgs. [cited by applicant]
“BVM—Blood Volume Monitor”, Fresenius Medical Care, [Online]. [Accessed May 23, 2018]. Retrieved from the Internet: <URL: http://fmc-au.com/pdf/machines/Blood%20Volume%20Monitor-Literature.pdf>, (2012), 14 pgs. [cited by applicant]
“European Application Serial No. 18808915.5, Extended European Search Report mailed Feb. 9, 2021”, 5 pgs. [cited by applicant]
“European Application Serial No. 18808915.5, Resposne filed Aug. 17, 2021 to Extended European Search Report mailed Feb. 9, 2021”, 24 pgs. [cited by applicant]
“International Application Serial No. PCT/US2018/035676, International Preliminary Report on Patentability mailed Dec. 12, 2019”, 9 pgs. [cited by applicant]
“International Application Serial No. PCT/US2018/035676, International Search Report mailed Aug. 29, 2018”, 2 pgs. [cited by applicant]
“International Application Serial No. PCT/US2018/035676, Written Opinion mailed Aug. 29, 2018”, 7 pgs. [cited by applicant]
Anne, Diroll, “Fluid Management during Hemodialysis”, NANT convention, available from the internet, (2016), 47 pgs. [cited by applicant]